Broisat A, Riou L M, Ardisson V, Boturyn D, Dumy P, Fagret D, Ghezzi C
INSERM, U340, Radiopharmaceutiques Biocliniques, 38700, La Tronche, France.
Eur J Nucl Med Mol Imaging. 2007 Jun;34(6):830-40. doi: 10.1007/s00259-006-0310-4. Epub 2007 Jan 12.
VCAM-1 plays a major role in the chronic inflammatory processes present in vulnerable atherosclerotic plaques. The residues 75-84 (B2702-p) and 84-75/75-84 (B2702-rp) of the major histocompatibility complex-1 (MHC-1) molecule B2702 were previously shown to bind specifically to VCAM-1. We hypothesised that radiolabelled B2702-p and B2702-rp might have potential for the molecular imaging of vascular cell adhesion molecule-1 (VCAM-1) expression in atherosclerotic plaques.
Preliminary biodistribution studies indicated that 125I-B2702-rp was unsuitable for in vivo imaging owing to extremely high lung uptake. 123I- or 99mTc-labelled B2702-p was injected intravenously to Watanabe heritable hyperlipidaemic rabbits (WHHL, n=6) and control animals (n=6). After 180 min, aortas were harvested for ex vivo autoradiographic imaging, gamma-well counting, VCAM-1 immunohistology and Sudan IV lipid staining.
Robust VCAM-1 immunostaining was observed in Sudan IV-positive and to a lesser extent in Sudan IV-negative areas of WHHL animals, whereas no expression was detected in control animals. Significant 2.9-fold and 1.9-fold increases in 123I-B2702-p and 99mTc-B2702-p aortic-to-blood ratios, respectively, were observed between WHHL and control animals (p<0.05). Tracer uptake on ex vivo images co-localised with atherosclerotic plaques. Image quantification indicated a graded increase in 123I-B2702-p and 99mTc-B2702-p activities from control to Sudan IV-negative and to Sudan IV-positive areas, consistent with the observed pattern of VCAM-1 expression. Sudan IV-positive to control area tracer activity ratios were 17.0+/-9.0 and 5.9+/-1.8 for 123I-B2702-p and 99mTc-B2702-p, respectively.
Radiolabelled B2702-p is a potentially useful radiotracer for the molecular imaging of VCAM-1 in atherosclerosis.
血管细胞黏附分子-1(VCAM-1)在易损动脉粥样硬化斑块中的慢性炎症过程中起主要作用。主要组织相容性复合体-1(MHC-1)分子B2702的75-84位残基(B2702-p)和84-75/75-84位残基(B2702-rp)先前已被证明能特异性结合VCAM-1。我们推测,放射性标记的B2702-p和B2702-rp可能具有对动脉粥样硬化斑块中血管细胞黏附分子-1(VCAM-1)表达进行分子成像的潜力。
初步的生物分布研究表明,由于肺部摄取极高,125I-B2702-rp不适合用于体内成像。将123I或99mTc标记的B2702-p静脉注射到渡边遗传性高脂血症兔(WHHL,n = 6)和对照动物(n = 6)体内。180分钟后,采集主动脉进行离体放射自显影成像、γ计数、VCAM-1免疫组织学检查和苏丹IV脂质染色。
在WHHL动物苏丹IV阳性区域观察到强烈的VCAM-1免疫染色,在苏丹IV阴性区域染色程度较轻,而在对照动物中未检测到表达。在WHHL和对照动物之间,观察到123I-B2702-p和99mTc-B2702-p的主动脉与血液比值分别显著增加2.9倍和1.9倍(p<0.05)。离体图像上的示踪剂摄取与动脉粥样硬化斑块共定位。图像定量显示,从对照到苏丹IV阴性区域再到苏丹IV阳性区域,123I-B2702-p和99mTc-B2702-p的活性呈分级增加,与观察到的VCAM-1表达模式一致。123I-B2702-p和99mTc-B2702-p的苏丹IV阳性区域与对照区域的示踪剂活性比值分别为17.0±9.0和5.9±1.8。
放射性标记的B2702-p是一种对动脉粥样硬化中VCAM-1进行分子成像的潜在有用放射性示踪剂。